Assignee
ALBIREO AB
SE·56 granted patents·23 pending applications·753 citations·filing 2004–2025
Top patents by PatentIndex Score
79 records- 0199US11572350B1Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2022·Granted Feb 7, 2023·17 cites·15 claims
- 0299US11267794B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Mar 8, 2022·21 cites·16 claims
- 0399US11180465B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Nov 23, 2021·25 cites·18 claims
- 0499US11111224B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Sep 7, 2021·30 cites·10 claims
- 0599US11014898B1Benzothiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted May 25, 2021·30 cites·25 claims
- 0698US12134606B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2023·Granted Nov 5, 2024·5 cites·19 claims
- 0798US11891368B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2022·Granted Feb 6, 2024·10 cites·17 claims
- 0898US11773071B2Benzothiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Oct 3, 2023·14 cites·15 claims
- 0998US11732006B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2021·Granted Aug 22, 2023·11 cites·10 claims
- 1098US11708340B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Jul 25, 2023·12 cites·17 claims
- 1198US11377429B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Jul 5, 2022·13 cites·5 claims
- 1298US11306064B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2020·Granted Apr 19, 2022·17 cites·21 claims
- 1398US11225466B2Benzothiadiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Jan 18, 2022·23 cites·20 claims
- 1498US10981952B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2020·Granted Apr 20, 2021·20 cites·12 claims
- 1598US10975045B2Benzothiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2020·Granted Apr 13, 2021·23 cites·9 claims
- 1698US10941127B2Benzothiadiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2020·Granted Mar 9, 2021·28 cites·14 claims
- 1798US10487111B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2018·Granted Nov 26, 2019·23 cites·10 claims
- 1898US10093697B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2017·Granted Oct 9, 2018·25 cites·8 claims
- 1998US10011633B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2017·Granted Jul 3, 2018·20 cites·7 claims
- 2098US10000528B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2017·Granted Jun 19, 2018·18 cites·8 claims
- 2198US9694018B1IBAT inhibitors for the treatment of liver diseaseALBIREO AB·Filed 2016·Granted Jul 4, 2017·47 cites·15 claims
- 2298US9688720B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2016·Granted Jun 27, 2017·27 cites·6 claims
- 2397US12202809B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2023·Granted Jan 21, 2025·4 cites·17 claims
- 2497US12187812B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2022·Granted Jan 7, 2025·3 cites·10 claims
- 2597US11603359B2Benzothiadiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2020·Granted Mar 14, 2023·11 cites·18 claims
- 2697US10975046B2Crystal modifications of odevixibatALBIREO AB·Filed 2019·Granted Apr 13, 2021·22 cites·20 claims
- 2797US10793534B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2019·Granted Oct 6, 2020·21 cites·10 claims
- 2897US10221212B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2018·Granted Mar 5, 2019·11 cites·8 claims
- 2996US12060338B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Aug 13, 2024·5 cites·15 claims
- 3096US12024495B2Benzothiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2021·Granted Jul 2, 2024·5 cites·10 claims
- 3196US11801226B2Pharmaceutical formulation of odevixibatALBIREO AB·Filed 2020·Granted Oct 31, 2023·11 cites·15 claims
- 3296US11583539B2Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitorsALBIREO AB·Filed 2021·Granted Feb 21, 2023·13 cites·29 claims
- 3396US11365182B2Crystal modifications of odevixibatALBIREO AB·Filed 2020·Granted Jun 21, 2022·10 cites·18 claims
- 3496US11261212B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2016·Granted Mar 1, 2022·17 cites·8 claims
- 3596US10786529B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2017·Granted Sep 29, 2020·12 cites·25 claims
- 3695US12187690B2Benzothiadiazepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2023·Granted Jan 7, 2025·4 cites·20 claims
- 3795US12091394B2Crystal modifications of odevixibatALBIREO AB·Filed 2022·Granted Sep 17, 2024·4 cites·27 claims
- 3895US11802115B2Pharmaceutical formulation of odevixibatALBIREO AB·Filed 2019·Granted Oct 31, 2023·11 cites·16 claims
- 3994US12365658B2Benzothia(di)azepine compounds and their use as bile acid modulatorsALBIREO AB·Filed 2022·Granted Jul 22, 2025·2 cites·16 claims
- 4093US10441605B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2017·Granted Oct 15, 2019·6 cites·22 claims
- 4193US10441604B2Cholestyramine pellets and methods for preparation thereofALBIREO AB·Filed 2017·Granted Oct 15, 2019·6 cites·18 claims
- 4293US2025326789A1Ibat inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2024·Application pending·0 cites
- 4391US11007142B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2018·Granted May 18, 2021·5 cites·21 claims
- 4491US10610543B2Cholestyramine pellets and methods for preparation thereofALBIREO AB·Filed 2018·Granted Apr 7, 2020·4 cites·19 claims
- 4590US7514421B2Use of an IBAT inhibitor for the treatment of constipationALBIREO AB·Filed 2004·Granted Apr 7, 2009·92 cites·4 claims
- 4688US10864228B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2018·Granted Dec 15, 2020·2 cites·30 claims
- 4788US10799527B2Oral cholestyramine formulation and use thereofALBIREO AB·Filed 2018·Granted Oct 13, 2020·2 cites·30 claims
- 4886US10881685B2Cholestyramine granules, oral cholestyramine formulations and use thereofALBIREO AB·Filed 2018·Granted Jan 5, 2021·2 cites·27 claims
- 4986US2025387449A1Pharmaceutical combination comprising an ibat inhibitor and a bile acid binderALBIREO AB·Filed 2025·Application pending·0 cites
- 5085US12545705B2IBAT inhibitors for the treatment of liver diseasesALBIREO AB·Filed 2025·Granted Feb 10, 2026·0 cites·2 claims
Showing the top 50 of 79 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →